Forecast horizon — calibration-scored at resolution.
By 2028, pembrolizumab-containing regimens will be first-line for >90% of eligible metastatic non-squamous NSCLC in US practice.
TL;DR · AI-generated
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi et al. · New England Journal of Medicine · 2018
· openalex W2796582438 · s2 45c4bb78
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1584
The KEYNOTE-189 trial's stated primary conclusion — Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations. — replicates in independent cohorts.
0.2013
By 2028, neoadjuvant checkpoint inhibition will be standard-of-care for stage II–III TNBC across major oncology guidelines.
0.2200
By 2028, 10-year survival data from CheckMate-067 will show a plateau ≥40% in the combination arm.
0.2264
PD-L1 tumor expression status will serve as a clinically validated predictive biomarker to guide selection between nivolumab monotherapy and combination nivolumab plus ipilimumab in metastatic melanoma.
0.2276
Recent follow-up analyses of KEYNOTE-522 are confirming the original effect size in real-world data.
0.2343
By 2028, antibody-drug conjugates (T-DXd class) will have largely displaced T-DM1 as second-line HER2+ metastatic therapy.